8-K: Atlantic Coastal Acquisition Corp. II Secures Non-Redemption Agreement with Key Investor

Atlantic Coastal Acquisition Corp. II entered into a non-redemption agreement with Sandia Investment Management LP, ensuring the reversal of potential share redemptions ahead of its business combination with Abpro Corporation.

Summary

• Atlantic Coastal Acquisition Corp. II (ACAB) has entered into a non-redemption agreement with Sandia Investment Management LP, representing certain investors.
• The agreement involves the investors reversing their previously submitted redemption demands for up to 124,352 shares of ACAB common stock.
• In return, upon the closing of the business combination with Abpro Corporation, ACAB will pay the investors a sum calculated as the redemption price per share minus $9.00, multiplied by the number of shares they hold.
• The agreement aims to reduce the number of shares redeemed, thereby increasing the cash available for the business combination.
• The redemption deadline was 5:00 p.m. Eastern Daylight time on November 5, 2024, two business days before the special meeting to approve the business combination on November 7, 2024.

Sentiment

Score: 7

Explanation: The document indicates a positive step towards completing the business combination by securing a non-redemption agreement. However, there are still risks and uncertainties associated with the transaction, which temper the overall sentiment.

Positives

• The non-redemption agreement secures a commitment from investors to retain their shares, reducing potential redemptions.
• This agreement provides more certainty for the business combination with Abpro Corporation.
• The agreement ensures that ACAB will have more cash available from its trust account for the business combination.
• The investors are incentivized to hold their shares through a payment structure that compensates them for not redeeming.

Negatives

• ACAB will need to pay investors a premium for reversing their redemption demands, which will reduce the cash available for the business combination.
• The agreement is contingent on the business combination closing, and if it does not, the agreement will terminate.

Risks

• The business combination with Abpro Corporation may not close by November 20, 2024, which would terminate the non-redemption agreement.
• There is a risk that the investors may not be able to sell their shares at a price higher than $9.00, which could impact their decision to reverse redemption demands.
• The agreement is subject to various conditions, and if these conditions are not met, the agreement may be terminated.
• The agreement includes a blocker provision that limits the number of shares the Backstop Investor can acquire upon exercise of warrants to 9.99% of the total issued and outstanding common stock.

Future Outlook

The document includes forward-looking statements regarding the business combination with Abpro, including the ability to close the transaction, obtain financing, and realize anticipated benefits. These statements are subject to various risks and uncertainties, and actual results may differ materially.

Management Comments

• The Company has entered into a non-redemption agreement to reduce potential redemptions.
• The Company is working towards completing the business combination with Abpro.

Industry Context

This announcement is typical for SPACs nearing a business combination, where securing investor support and minimizing redemptions is crucial for the transaction's success. Non-redemption agreements are a common tool used to ensure sufficient capital remains in the trust account.

Comparison to Industry Standards

• The use of non-redemption agreements is a common practice among SPACs to mitigate the risk of high redemptions prior to a business combination.
• The terms of the agreement, including the payment structure and the cap on shares, are consistent with industry standards for such agreements.
• The redemption price of approximately $11.22 is typical for SPACs that have not experienced significant market fluctuations.
• Comparable companies that have used similar agreements include other SPACs such as those that have merged with biotech companies, for example, the merger between CM Life Sciences and Sema4.

Stakeholder Impact

• Shareholders will be impacted by the reduced redemption risk and the potential for the business combination to be completed.
• The investors involved in the non-redemption agreement will receive a payment for reversing their redemption demands.
• The company will have more cash available for the business combination, which could benefit the combined entity.

Next Steps

• The company will proceed with the special meeting of shareholders on November 7, 2024, to approve the business combination.
• The company will work towards closing the business combination with Abpro by November 20, 2024.
• The company will pay the non-redemption cash to the investors upon the consummation of the business combination.

Key Dates

Keywords

non-redemption agreement, business combination, redemption, ACAB, Abpro, Sandia Investment Management, SPAC, merger, investors, trust account